185 related articles for article (PubMed ID: 21988406)
1. Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.
Yue Y; Xu W; Xiong S
DNA Cell Biol; 2012 Apr; 31(4):479-88. PubMed ID: 21988406
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
3. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
Yue Y; Xu W; Hu L; Jiang Z; Xiong S
Virology; 2009 Apr; 386(2):438-47. PubMed ID: 19233446
[TBL] [Abstract][Full Text] [Related]
4. M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine.
Ye T; Yue Y; Fan X; Dong C; Xu W; Xiong S
Vaccine; 2014 Jul; 32(35):4457-4465. PubMed ID: 24958702
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.
Wang M; Yue Y; Dong C; Li X; Xu W; Xiong S
Clin Vaccine Immunol; 2013 Nov; 20(11):1743-51. PubMed ID: 24027262
[TBL] [Abstract][Full Text] [Related]
6. Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.
Chai D; Yue Y; Xu W; Dong C; Xiong S
Hum Vaccin Immunother; 2014; 10(5):1284-94. PubMed ID: 24614684
[TBL] [Abstract][Full Text] [Related]
7. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
8. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis.
Wu F; Fan X; Yue Y; Xiong S; Dong C
Vaccine; 2014 Jun; 32(31):3917-26. PubMed ID: 24874923
[TBL] [Abstract][Full Text] [Related]
9. AIM2 co-immunization favors specific multifunctional CD8(+) T cell induction and ameliorates coxsackievirus B3-induced chronic myocarditis.
Chai D; Yue Y; Xu W; Dong C; Xiong S
Antiviral Res; 2015 Jul; 119():68-77. PubMed ID: 25956163
[TBL] [Abstract][Full Text] [Related]
10. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
Xu W; Shen Y; Jiang Z; Wang Y; Chu Y; Xiong S
Vaccine; 2004 Sep; 22(27-28):3603-12. PubMed ID: 15315839
[TBL] [Abstract][Full Text] [Related]
11. A parenteral DNA vaccine protects against pneumonic plague.
Yamanaka H; Hoyt T; Yang X; Bowen R; Golden S; Crist K; Becker T; Maddaloni M; Pascual DW
Vaccine; 2010 Apr; 28(18):3219-30. PubMed ID: 20197132
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus.
Wang X; Zhang X; Kang Y; Jin H; Du X; Zhao G; Yu Y; Li J; Su B; Huang C; Wang B
Vaccine; 2008 Sep; 26(40):5135-44. PubMed ID: 18462848
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route.
Qi X; Lu Q; Hu J; Xiong S
Microb Cell Fact; 2019 Apr; 18(1):66. PubMed ID: 30947747
[TBL] [Abstract][Full Text] [Related]
14. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
15. An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine.
Gao Y; Yue Y; Xiong S
Front Immunol; 2021; 12():666594. PubMed ID: 34630378
[No Abstract] [Full Text] [Related]
16. Mesenteric CD103
Zhao H; Yang J; Qian Q; Wu M; Li M; Xu W
Front Immunol; 2018; 9():2986. PubMed ID: 30619341
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
18. [A novel DNA vaccine containing endosome-fusogenic peptide prevents CVB3-induced myocarditis in mice].
Xu W; Shen Y; Chen RZ; Xiong SD
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):334-8. PubMed ID: 15059520
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
[TBL] [Abstract][Full Text] [Related]
20. Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis.
Zhang C; Zhang Y; Li Y; Lu J; Xiong S; Yue Y
Virology; 2023 Feb; 579():46-53. PubMed ID: 36603532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
